Treatment of Bronchospasm with Persistent Rhonchi

First-Line Bronchodilator Therapy

The American College of Chest Physicians recommends administering nebulized albuterol 2.5 mg in 3 cc normal saline for acute bronchospasm, with onset of action within 15-30 minutes, peak effect at 1-2 hours, and duration of 4-5 hours, as the primary treatment for acute bronchospasm in patients with reversible obstructive airway disease 1
Ipratropium provides significant additive benefit when combined with beta-agonists for persistent bronchospasm, particularly in patients on beta-blockers, where ipratropium becomes the treatment of choice 1

For bronchospasm with gradual deterioration or inadequate response to bronchodilators, the American Thoracic Society recommends adding methylprednisolone 40-60 mg/day, as systemic corticosteroids are recommended when there is persistent bronchospasm despite initial bronchodilator therapy 1
In chronic bronchitis with persistent rhonchi, inhaled corticosteroids combined with long-acting beta-agonists reduce exacerbation rates and improve cough, according to the American College of Chest Physicians 2

In patients taking beta-blockers, the American Heart Association recommends using ipratropium as first-line therapy rather than albuterol, as epinephrine and beta-agonists may paradoxically worsen symptoms through unopposed alpha-adrenergic effects 1
In chronic bronchitis, ipratropium has been shown to reduce cough frequency, severity, and sputum volume, according to the American College of Chest Physicians 2

The American College of Chest Physicians recommends administering supplemental oxygen to patients with prolonged bronchospasm, hypoxemia, or requiring multiple treatments 1

Leukotriene inhibitors, such as montelukast, or 5-lipoxygenase inhibitors, such as zileuton, may reduce bronchospasm in select patients, particularly if urinary LTE4 levels are increased, according to the American Academy of Allergy, Asthma, and Immunology 3